Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk: A Rare Second Chance
Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite recent setbacks. Novo Nordisk's Q3/25 results showed slowing growth, lowered guidance, and intensifying competition, but double-digit growth and strong pipeline remain intact. Valuation is compelling: Novo Nordisk trades near its lowest P/E in 20 years and offers a solid free cash flow yield, with intrinsic value estimates well above current price.
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
Novo Nordisk said it is lowering the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic to $349 per month from $499 per month for existing cash-paying patients. The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of the drugs for $199 per month for the first two months of treatment.
Novo Nordisk rolls out $349 Wegovy cash price ahead of plan
Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ahead of the timeline set out with the Trump administration.
Novo Nordisk Stock: Buy And Forget
Novo Nordisk A/S shares have declined more than 50% over the past 12 months. Competition in the obesity and type 2 diabetes market and pricing pressure from the U.S. government have weighed on NVO results. I think NVO stock is a long-term value play that pays a nice dividend in the meantime.
Retail Investors Really Don't Like Novo Nordisk (NVO) Stock
Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.
Novo Nordisk shareholders approve new board chair
Novo Nordisk's shareholders have approved Lars Rebien Sorensen as the company's new chairman in an extraordinary shareholder meeting, the company said on Friday.
Novo: The Double Bottom Is In
Novo Nordisk remains a compelling long-term healthcare compounder, despite mixed Q3 results and recent stock weakness. NVO's growth is driven by global obesity drug demand, robust pipeline development, and manufacturing scale, with Wegovy's international uptake and oral pill potential as key catalysts. Valuation is attractive with limited downside, fair sector-relative pricing, and technical signals suggesting a double bottom and bullish momentum.
Novo Nordisk: Long-Term Brand Dominance At A Bargain
Dominant mega-caps with low debt deserve investors' attention. In times of prosperity, waste is common—and often sets the stage for strong cash generation when the cycle turns. Novo is enacted solid counter-measures: the CVS deal, the crackdown on compounders, and aggressive cost cutting.
Novo Nordisk: Reliable Weigh-Loss Growth Story With More Upside Than Bears Admit
Novo Nordisk is significantly undervalued after a 20% stock price decline, now trading at a forward P/E of 13. NVO maintains strong growth prospects, driven by obesity treatment market expansion, international rollout, and cardiovascular label extensions. Recent drug-pricing agreements have reduced uncertainty, and most risks appear priced in, supporting a bullish long-term outlook for NVO.
This biotech is halting its work with Novo Nordisk and laying off more people
Korro is the latest to rethink its ties with the Danish pharma company.
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
